top of page

IGT Statement on the Introduction of the Medicaid VBPs for Patients Act (H.R. 7389)

WASHINGTON, DC (April 5, 2022) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following statement regarding the introduction of the Medicaid VBPs for Patients Act, or the MVP Act (H.R. 7389):

“We applaud Representatives Kurt Schrader (D-OR), Brett Guthrie (R-KY), and Markwayne Mullin (R-OK) for recognizing that patients’ ability to access gene therapies is imperative to realizing the promise of these transformative treatments. This bipartisan bill builds on the work of the Centers for Medicare & Medicaid Services (CMS), which has established clear pathways to value-based purchasing (VBP) arrangements for manufacturers, payers, and providers.

“The nature of gene therapies as one-time, long-lasting treatments for some of the most severe diseases creates unique reimbursement challenges. Policymakers have recognized this reality and are taking action so that access barriers do not delay the delivery of current and future potentially life-saving therapies to patients.

“We look forward to working with Congress and stakeholders from the community to build support for this important piece of legislation.”


About the Institute for Gene Therapies

The Institute for Gene Therapies brings together experts from across the healthcare system to advocate for a modernized policy framework that encourages innovations and promotes patient access to the treatments they need. We represent innovators and patients, business leaders and academics working to ensure policies reflect medical advances, creating a new reality for patients. Follow us on Twitter @gene_therapies.


bottom of page